Abstract

BackgroundMounting reports on severe Plasmodium vivax malaria from across the globe have raised concerns among the scientific community. However, the risk of P. vivax resulting in complicated malaria and mortality is not as firmly established as it is with Plasmodium falciparum. This study was conducted to determine the severity proportion and factors associated with severity in cases of vivax and falciparum malaria.MethodsAdult patients microscopically diagnosed to have P. vivax/P. falciparum infections from the year 2007-2011 were evaluated based on their hospital records. Severe malaria was defined as per the World Health Organization’s guidelines. Comparison was made across species and binary logistic regression was used to determine risk factors of severity.ResultsOf 922 malaria cases included in the study, P. vivax was the largest (63.4%, 95% confidence interval (CI) 60.3-66.5%) infecting species, followed by P. falciparum (34.4%, 95% CI 31.3-37.5%) and their mixed infection (2.2%, 95% CI 1.3-3.2%). Severity in P. vivax and P. falciparum was noted to be 16.9% (95% CI 13.9-19.9%) and 36.3% (95% CI 31.0-41.6%) respectively. Plasmodium falciparum had significantly higher odds [adjusted odds ratio (95% CI), 2.80 (2.04-3.83)] of severe malaria than P. vivax. Rising respiratory rate [1.29 (1.15-1.46)], falling systolic blood pressure [0.96 (0.93-0.99)], leucocytosis [12.87 (1.43-115.93)] and haematuria [59.36 (13.51-260.81)] were the independent predictors of severity in P. vivax. Increasing parasite index [2.97 (1.11-7.98)] alone was the independent predictor of severity in P. falciparum. Mortality in vivax and falciparum malaria was 0.34% (95% CI -0.13-0.81%) and 2.21% (95% CI 0.59-3.83%), respectively. Except hyperparasitaemia and shock, other complications were associated (P < 0.05) with mortality in falciparum malaria. Pulmonary oedema/acute respiratory distress syndrome was associated (P = 0.003) with mortality in vivax malaria. Retrospective design of this study possesses inherent limitations.ConclusionsPlasmodium vivax does cause severe malaria and mortality in substantial proportion but results in much lesser amalgamations of multi-organ involvements than P. falciparum. Pulmonary oedema/acute respiratory distress syndrome in P. vivax infection could lead to mortality and therefore should be diagnosed and treated promptly. Mounting complications and its broadening spectrum in ‘not so benign’ P. vivax warrants global vigilance for any probable impositions.Electronic supplementary materialThe online version of this article (doi:10.1186/1475-2875-13-304) contains supplementary material, which is available to authorized users.

Highlights

  • Mounting reports on severe Plasmodium vivax malaria from across the globe have raised concerns among the scientific community

  • Plasmodium vivax was the largest (63.4%, 585/922) infecting malaria species followed by P. falciparum (34.4%, 317/922) and their mixed infections (2.2%, 20/922) (Figure 1)

  • In adult malaria, the spectrum of severity may be extensively different among various populations with diverse endemicity

Read more

Summary

Introduction

Mounting reports on severe Plasmodium vivax malaria from across the globe have raised concerns among the scientific community. The risk of P. vivax resulting in complicated malaria and mortality is not as firmly established as it is with Plasmodium falciparum. There has been a gradual increase in reports describing sporadic atypical manifestations [1,2,3,4] to wide spectrum severity [5,6,7] among Plasmodium vivax patients from India and other parts of the globe. Of late this clamour on the rising severity in P. vivax malaria has raised concerns among the scientific community. In the existing literature from India and elsewhere, studies have been either case reports [1,2,3], or have lacked a denominator or comparison with other malaria species [7] or multivariate logistic regression analysis [6,7,10], or have described exiguous complications [11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call